Showing results (1091-1100 of 1,129) with videos related to

Sort By:
Pageof 113
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
American Journal of Hematology|July 20, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter studyYi Zhang, Hu Zhou, Minghui Duan, et al.
Blood Cancer Journal|December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomesSijian Yu, Tong Lin, Danian Nie, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2021
Csi-let-7a-5p delivered by extracellular vesicles from a liver fluke activates M1-like macrophages and exacerbates biliary injuriesChao Yan, Qian-Yang Zhou, Jing Wu, et al.
Experimental Hematology & Oncology|June 21, 2023
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia veraJie Jin, Lei Zhang, Albert Qin, et al.
Nature Communications|April 16, 2021
Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitorZizheng Zou, Xiyuan Hu, Tiao Luo, et al.
Journal of Hematology & Oncology|April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialHua Jin, Yu Zhang, Sijian Yu, et al.
British Journal of Haematology|May 21, 2025
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort studyYiling Ye, Xinyu Liu, Huajuan Dai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort StudyGuopan Yu, Yu Zhang, Sijian Yu, et al.
The Lancet. Haematology|July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialLi Xuan, Yu Wang, Kaibo Yang, et al.
Pageof 113